United States· US:63029-912_871f81c0-8d71-4ff5-8317-9a1f74ba7b83
DRAMAMINE
A medicinal product containing meclizine dihydrochloride, registered in United States by Medtech Products Inc..
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- MECLIZINE DIHYDROCHLORIDE
- Manufacturer
- Medtech Products Inc.
- Country
- United States (US)
- ATC code
- —
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc1163029-912-04
- ndc1163029912044 POWDER in 1 BOX (63029-912-04)
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Meclizine dihydrochloride in 9 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- SpainCHICLIDA 25 mg CHICLES MEDICAMENTOSOSFleer Española S.L.
- FinlandPostafenParanova Oy
- BelgiumAgyrax 25 mgMediXal
- FranceAGYRAX, comprimé sécableMEDIXAL
- United KingdomSea-Legs 12.5mg tabletsG.R. Lane Health Products Ltd
- NorwayAgyrax2care4 ApS
- IcelandPostafenCampusPharma AB
- SwedenPostafen 25 mg TablettCampus Pharma AB
Authorised across Europe · EMA
The same active substance is authorised in 12 EEA countries. Names it is sold under:
- Belgium · Agyrax, Postafene
- Denmark · Postafen
- Spain · Chiclida
- Finland · Postafen
- France · Agyrax, Navidoxine
- United Kingdom (Northern Ireland) · Sea-Legs, Traveleeze
- Greece · Emetostop
- Iceland · Postafen
- Luxembourg · Agyrax, Postafene
- Netherlands · Suprimal
- Norway · Postafen
- Sweden · Postafen
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/0b3ecf0c-daf9-49fa-b6ec-93d756e28589 GET /v1/drugs/0b3ecf0c-daf9-49fa-b6ec-93d756e28589?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "50",
"substance": "MECLIZINE DIHYDROCHLORIDE",
"productndc": "63029-912",
"dosage_form": "POWDER",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "M009",
"marketing_category": "OTC MONOGRAPH DRUG"
}See everything about meclizine dihydrochloride.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.